VANTIA THERAPEUTICS
Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, which directly target indications that together affect many millions of people, are poorly treated and represent billion dollar markets. Vantia's strategy is to develop its proprietary drug candidates through Phase II clinical testing and then commercialise through partnerships. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.
VANTIA THERAPEUTICS
Social Links:
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2007-01-01
Address:
Chilworth, Hampshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.vantia.com
Total Employee:
11+
Status:
Active
Contact:
44 11 7916 7693
Email Addresses:
[email protected]
Total Funding:
6.5 M USD
Technology used in webpage:
SPF LetsEncrypt Apache IPv6 Google Apps For Business 20i 20i DNS Node4
Similar Organizations
BioXpress Therapeutics
BioXpress Therapeutics SA is a premier provider of high-quality biologic APIs for unmet need indications.
Current Advisors List
Current Employees Featured
Founder
Investors List
MVM Life Science Partners
MVM Life Science Partners investment in Series B - Vantia Therapeutics
SV Health Investors
SV Health Investors investment in Series B - Vantia Therapeutics
Novo Holdings
Novo Holdings investment in Series B - Vantia Therapeutics
Novo Ventures
Novo Ventures investment in Seed Round - Vantia Therapeutics
Official Site Inspections
http://www.vantia.com
- Host name: 185-151-30-138.ptr4.stackcp.net
- IP address: 185.151.30.138
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
